<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144755</url>
  </required_header>
  <id_info>
    <org_study_id>LNH03-6B</org_study_id>
    <nct_id>NCT00144755</nct_id>
  </id_info>
  <brief_title>R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentric randomized trial evaluating the efficacy and safety of R-CHOP&#xD;
      given every 14 days compared to R-CHOP given every 21 days in association or not with&#xD;
      darbepoetin alfa in order to maintain hemoglobin above 13 g/dl, compared to classical&#xD;
      symptomatic treatment of anemia in patients aged from 60 to 80 years with diffuse large&#xD;
      B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients aged 60 to 75 years with diffuse large B-cell lymphoma, the shortening of&#xD;
      interval between the courses of CHOP combination (CHOP-14), improves the complete response&#xD;
      rate, the progression free survival and the overall survival.&#xD;
&#xD;
      The addition of Rituximab to standard CHOP (R-CHOP) has also been shown to improve complete&#xD;
      remission rate (CR), event-free survival (EFS) and overall survival (OS) in elderly patients&#xD;
      with B-DLCL.&#xD;
&#xD;
      The aim of this study is to test the hypothesis that the increase of the dose intensity by&#xD;
      shortening the interval between two courses of R-CHOP (R-CHOP-14)could further improve the&#xD;
      results of the R-CHOP.&#xD;
&#xD;
      Anemia is frequent at diagnosis and during the treatment of aggressive lymphoma. In the&#xD;
      previous LNH 98-5 study, 72 % of the patients had, at the diagnosis, a hemoglobin level&#xD;
      inferior to 13 g/dl. Moreover, during the treatment, 92 % of the patients had a hemoglobin&#xD;
      level less than 13 g/dl and 30 % were transfused. The presence of anemia at diagnosis is an&#xD;
      indicator of poor prognosis in multivariate analysis. This prognosis impact could probably be&#xD;
      explained at cellular level on the tumor. Tumoral hypoxia is increased by the presence of&#xD;
      anemia. Due to this hypoxia, the expression of tumor growth factor may be increased: e.a VEGF&#xD;
      and the induction of expression of multi drug resistance (MDR1) is observed. This resistance&#xD;
      to treatment is also due to the inhibition of genotoxic activity of free radicals induced by&#xD;
      ionised radiation and chemotherapy. Experimentally, the negative impact of hypoxia on the&#xD;
      efficacy of chemotherapy has been demonstrated in sarcoma cell lines for doxorubicin,&#xD;
      vincristine and all most cyclophosphamide. Finally, hypoxia induced over expression of&#xD;
      apoptosis resistance genes and induced a growth advantage for apoptosis resistant tumoral&#xD;
      lines. Improvement of survival in patients receiving erythropoetin with chemotherapy or&#xD;
      radiotherapy was suggested in a study on patients treated with a neoadjuvant&#xD;
      radiochemotherapy for head and neck cancer. Erythropoetin could act to protect several normal&#xD;
      tissues during chemotherapy and thus could decrease treatment related morbidity. Darbepoetin&#xD;
      alfa is a new recombinant protein stimulating erythropoiesis. Thus, the use of darbepoetin&#xD;
      alfa, in association with chemotherapy, could increase CR rate, EFS and OS in patients&#xD;
      treated for diffuse large B-cell lymphoma.&#xD;
&#xD;
      This study is a multicentric, phase III open-label, randomized trial evaluating the efficacy&#xD;
      and safety of R-CHOP given every 14 days compared to R-CHOP given every 21 days in&#xD;
      association or not with darbepoetin alfa in order to maintain hemoglobin above 13 g/dl,&#xD;
      compared to classical symptomatic treatment of anemia in patients aged 66 to 80 years with&#xD;
      not previously treated diffuse large B-cell lymphoma with at least one adverse prognostic&#xD;
      factor of the age adjusted IPI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of R-CHOP 14 vs R-CHOP 21 measured by event-free survival (EFS)</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of darbepoetin alfa in association with chemotherapy measured by the EFS.</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and toxicity of R-CHOP 14 vs R-CHOP 21</measure>
    <time_frame>8 years</time_frame>
    <description>CR rate, DFS, OS, dose intensity and additional toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and toxicity of Darbepoetin alfa in association with R-CHOP.</measure>
    <time_frame>8 years</time_frame>
    <description>event-free survival</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 cycles of R-CHOP21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP21, Darbepoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of R-CHOP21 + prophylactic darbepoetin alfa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of R-CHOP14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP14, Darbepoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of R-CHOP14 + prophylactic darbepoetin alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>prophylactic administration of darbepoetin alfa in experimental arm</description>
    <arm_group_label>R-CHOP14</arm_group_label>
    <arm_group_label>R-CHOP14, Darbepoetin alfa</arm_group_label>
    <arm_group_label>R-CHOP21</arm_group_label>
    <arm_group_label>R-CHOP21, Darbepoetin alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with histologically proven CD20+ diffuse large B cell lymphoma (WHO&#xD;
        Classification).&#xD;
&#xD;
        Aged 66 to 80 years old. Patients not previously treated. Ann Arbor stage II, III, IV. ECOG&#xD;
        performance status 0 to 2. Age-adjusted IPI equal to 1, 2, or 3. With a minimum life&#xD;
        expectancy of 3 months. Negative HIV, HBV and HCV serologies test &lt; 4 weeks (except after&#xD;
        vaccination for HBV).&#xD;
&#xD;
        Having signed a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any other histological type of lymphoma. Any history of treated or non-treated indolent&#xD;
        lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell&#xD;
        lymphoma with some small cell infiltration in bone marrow or lymph node may be included.&#xD;
&#xD;
        Central nervous system or meningeal involvement by lymphoma. Contra-indication to any drug&#xD;
        contained in the chemotherapy regimens. Any serious co-morbid active disease (according to&#xD;
        the investigator's decision).&#xD;
&#xD;
        Poor renal function (creatinin level &gt; 150 micromol/l), poor hepatic function (total&#xD;
        bilirubin level &gt; 30mmol/l, transaminases &gt; 2.5 maximum normal level) unless these&#xD;
        abnormalities are related to the lymphoma.&#xD;
&#xD;
        Poor bone marrow reserve as defined by neutrophils &lt; 1.5 G/l or platelets &lt; 100 G/l, unless&#xD;
        related to bone marrow infiltration.&#xD;
&#xD;
        Any history of cancer during the last 5 years with the exception of non-melanoma skin&#xD;
        tumors or stage 0 (in situ) cervical carcinoma.&#xD;
&#xD;
        Uncontrolled hypertension. Known hypersensitivity to erythropoietin. Myocardial infarction&#xD;
        during last 3 month, or unstable coronary disease, or uncontrolled cardiac insufficiency.&#xD;
&#xD;
        Venous thrombosis or pulmonary embolism during last 3 months. Treatment with any&#xD;
        investigational drug within 30 days before planned first cycle of chemotherapy and during&#xD;
        the study.&#xD;
&#xD;
        Pregnant or lactating women. Adult patient under tutelage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Delarue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Bosly, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Tilly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université de Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie Adultes - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweirische Arbeitsgruppe fur klinische Krebsforschung</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. Epub 2005 May 2.</citation>
    <PMID>15867204</PMID>
  </reference>
  <reference>
    <citation>Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11.</citation>
    <PMID>15016643</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma, diffuse large B-cell</keyword>
  <keyword>rituximab</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>erythropoetin</keyword>
  <keyword>darbepoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

